Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074403938> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- W2074403938 endingPage "e71" @default.
- W2074403938 startingPage "e71" @default.
- W2074403938 abstract "In the letter by Mohr et al, it is proposed that a crucial aspect not addressed by our study relates to patients’ quality of life during long-term treatment with high-dose interferon alfa-2b (IFN-2b). A quality-of-life questionnaire was not completed by patients who participated in our study, but toxicity was recorded and graded according to the National Cancer Institute Common Toxicity Criteria. This was decided in 1997 by the protocol team, and patients presenting with psychiatric disorders were assessed by psychiatrists. Rates of psychiatric disorders of any grade were higher in arm B (receiving 1 month of high-dose IFN-2b intravenously followed by 48 weeks of maintenance therapy with 15 10 U/m of IFN-2b subcutaneously three times per week), but a majority of adverse events were of grades 1 to 2 in severity. Psychiatric disorders involved depressive episodes, mood instability, mania, and irritability. We agree that depression seems to have a low impact on IFN-2b tolerability, which is in accordance with the presentation on the German Dermatologic Cooperative Oncology Group trial at the 2007 ASCO Annual Meeting and the article by Bannink et al. However, as the mechanisms underlying fatigue, depression and cognitive slowing associated with IFNtherapy seem to be largely mediated by the direct and indirect effects of IFNon the hypothalamus. Because the different criteria and methods used by researchers make the actual incidence of depression difficult to ascertain, the final results of the German Dermatologic Cooperative Oncology Group trial are awaited with interest." @default.
- W2074403938 created "2016-06-24" @default.
- W2074403938 creator A5012112204 @default.
- W2074403938 creator A5055480892 @default.
- W2074403938 creator A5090633646 @default.
- W2074403938 date "2009-08-20" @default.
- W2074403938 modified "2023-09-25" @default.
- W2074403938 title "Reply to P. Mohr et al" @default.
- W2074403938 cites W1981218605 @default.
- W2074403938 cites W2044389879 @default.
- W2074403938 cites W2084830756 @default.
- W2074403938 cites W2141621284 @default.
- W2074403938 cites W2525800031 @default.
- W2074403938 doi "https://doi.org/10.1200/jco.2009.23.5333" @default.
- W2074403938 hasPublicationYear "2009" @default.
- W2074403938 type Work @default.
- W2074403938 sameAs 2074403938 @default.
- W2074403938 citedByCount "0" @default.
- W2074403938 crossrefType "journal-article" @default.
- W2074403938 hasAuthorship W2074403938A5012112204 @default.
- W2074403938 hasAuthorship W2074403938A5055480892 @default.
- W2074403938 hasAuthorship W2074403938A5090633646 @default.
- W2074403938 hasBestOaLocation W20744039381 @default.
- W2074403938 hasConcept C71924100 @default.
- W2074403938 hasConceptScore W2074403938C71924100 @default.
- W2074403938 hasIssue "24" @default.
- W2074403938 hasLocation W20744039381 @default.
- W2074403938 hasOpenAccess W2074403938 @default.
- W2074403938 hasPrimaryLocation W20744039381 @default.
- W2074403938 hasRelatedWork W1506200166 @default.
- W2074403938 hasRelatedWork W1995515455 @default.
- W2074403938 hasRelatedWork W2048182022 @default.
- W2074403938 hasRelatedWork W2080531066 @default.
- W2074403938 hasRelatedWork W2604872355 @default.
- W2074403938 hasRelatedWork W2748952813 @default.
- W2074403938 hasRelatedWork W2899084033 @default.
- W2074403938 hasRelatedWork W3031052312 @default.
- W2074403938 hasRelatedWork W3032375762 @default.
- W2074403938 hasRelatedWork W3108674512 @default.
- W2074403938 hasVolume "27" @default.
- W2074403938 isParatext "false" @default.
- W2074403938 isRetracted "false" @default.
- W2074403938 magId "2074403938" @default.
- W2074403938 workType "article" @default.